| Biological Sciences | Lifetime | 71 | US 43 | 99.99 |
| Medical and Health Sciences | Lifetime | 180 | US 99 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 115 | US 47 | 99.98 |
| Biological Sciences | 2021-2025 | 222 | US 41 | 99.78 |
| Psychology and Behavioral Sciences | 2021-2025 | 321 | US 98 | 99.23 |
| Cellular and Molecular Neuroscience | Lifetime | 8 | US 5 | 99.98 |
| Clinical Pharmacology | Lifetime | 38 | US 19 | 99.83 |
| Cognitive Neuroscience | Lifetime | 67 | US 36 | 99.87 |
| Public, Environmental and Occupational Health | Lifetime | 150 | US 76 | 99.77 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 296 | US 169 | 99.28 |
| Psychiatry and Mental health | Lifetime | 170 | US 82 | 99.50 |
| Epidemiology | Lifetime | 564 | US 286 | 99.30 |
| Medical Physiology | Lifetime | 802 | US 407 | 98.51 |
| Clinical Psychology | Lifetime | 853 | US 523 | 98.71 |
| Pediatrics, Perinatology and Child Health | Lifetime | 599 | US 290 | 98.16 |
| Clinical Neurology | Lifetime | 515 | US 230 | 97.70 |
| Endocrine and Autonomic Systems | Lifetime | 253 | US 127 | 95.82 |
| Toxicology | Lifetime | 118 | US 32 | 94.63 |
| Public, Environmental and Occupational Health | 2021-2025 | 10 | US 6 | 99.93 |
| Cellular and Molecular Neuroscience | 2021-2025 | 6 | US 4 | 99.41 |
| Clinical Pharmacology | 2021-2025 | 9 | US 3 | 99.39 |
| Epidemiology | 2021-2025 | 89 | US 25 | 99.48 |
| Cognitive Neuroscience | 2021-2025 | 52 | US 20 | 99.19 |
| Pediatrics, Perinatology and Child Health | 2021-2025 | 118 | US 42 | 98.19 |
| Clinical Psychology | 2021-2025 | 358 | US 142 | 97.10 |
| Medical Physiology | 2021-2025 | 310 | US 109 | 95.82 |
| Psychiatry and Mental health | 2021-2025 | 200 | US 73 | 95.81 |
| Neurotransmitter Receptor Influence on Behavior | Lifetime | 4 | US 3 | 99.98 |
| Opioid Use Disorder Treatment | Lifetime | 3 | US 1 | 99.87 |
| Cannabis and Cannabinoid Research | Lifetime | 9 | US 6 | 99.83 |
| Attention Deficit Hyperactivity Disorder | Lifetime | 12 | US 7 | 99.83 |
| Functional Brain Connectivity Studies | Lifetime | 28 | US 19 | 99.91 |
| Receptor Mechanisms and Signaling | Lifetime | 40 | US 25 | 99.79 |
| Forensic Toxicology and Drug Analysis | Lifetime | 7 | US 3 | 99.59 |
| Medical Imaging Techniques and Applications | Lifetime | 66 | US 33 | 99.50 |
| Neural and Behavioral Psychology Studies | Lifetime | 23 | US 15 | 99.81 |
| Neuroscience and Neuropharmacology Research | Lifetime | 80 | US 49 | 99.84 |
| Prenatal Substance Exposure Effects | Lifetime | 13 | US 9 | 99.41 |
| Substance Abuse Treatment and Outcomes | Lifetime | 26 | US 18 | 99.61 |
| Diet and metabolism studies | Lifetime | 151 | US 68 | 99.62 |
| Regulation of Appetite and Obesity | Lifetime | 44 | US 25 | 99.50 |
| Pain Management and Opioid Use | Lifetime | 29 | US 20 | 99.44 |
| Advanced MRI Techniques and Applications | Lifetime | 172 | US 87 | 99.44 |
| Nicotinic Acetylcholine Receptors Study | Lifetime | 65 | US 34 | 99.12 |
| Pharmacology and Obesity Treatment | Lifetime | 79 | US 42 | 98.88 |
| Treatment of Major Depression | Lifetime | 99 | US 50 | 99.10 |
| Memory and Neural Mechanisms | Lifetime | 177 | US 100 | 98.88 |
| Heart Rate Variability and Autonomic Control | Lifetime | 444 | US 206 | 98.47 |
| Neurological and metabolic disorders | Lifetime | 86 | US 43 | 97.76 |
| Eating Disorders and Behaviors | Lifetime | 254 | US 128 | 98.24 |
| Advanced Neuroimaging Techniques and Applications | Lifetime | 359 | US 174 | 98.48 |
| Alcoholism and Thiamine Deficiency | Lifetime | 80 | US 49 | 97.20 |
| Parkinson's Disease Mechanisms and Treatments | Lifetime | 562 | US 204 | 98.19 |
| Sleep and Wakefulness Research | Lifetime | 396 | US 190 | 97.62 |
| Neural dynamics and brain function | Lifetime | 752 | US 352 | 98.14 |
| Biochemical Analysis and Sensing Techniques | Lifetime | 569 | US 246 | 96.81 |
| Mental Health Research Topics | Lifetime | 584 | US 326 | 97.33 |
| Tryptophan and brain disorders | Lifetime | 899 | US 361 | 96.26 |
| Pharmacological Receptor Mechanisms and Effects | Lifetime | 291 | US 159 | 95.66 |
| Smoking Behavior and Cessation | Lifetime | 586 | US 397 | 95.78 |
| Health, Environment, Cognitive Aging | Lifetime | 393 | US 196 | 94.76 |
| Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes | Lifetime | 774 | US 377 | 96.17 |
| Poisoning and overdose treatments | Lifetime | 427 | US 209 | 93.80 |
| Opioid Use Disorder Treatment | 2021-2025 | 2 | US 2 | 99.90 |
| Substance Abuse Treatment and Outcomes | 2021-2025 | 2 | US 1 | 99.82 |
| Neurotransmitter Receptor Influence on Behavior | 2021-2025 | 2 | US 2 | 99.86 |
| Prenatal Substance Exposure Effects | 2021-2025 | 3 | US 2 | 99.58 |
| Pain Management and Opioid Use | 2021-2025 | 4 | US 3 | 99.49 |
| Functional Brain Connectivity Studies | 2021-2025 | 83 | US 26 | 98.84 |
| Cannabis and Cannabinoid Research | 2021-2025 | 25 | US 7 | 98.38 |
| Attention Deficit Hyperactivity Disorder | 2021-2025 | 28 | US 6 | 98.29 |
| Treatment of Major Depression | 2021-2025 | 59 | US 20 | 96.91 |
| Birth, Development, and Health | 2021-2025 | 330 | US 120 | 94.91 |
| Diabetes Treatment and Management | 2021-2025 | 321 | US 110 | 96.48 |
| Diet and metabolism studies | 2021-2025 | 687 | US 204 | 94.07 |
| Forensic Toxicology and Drug Analysis | 2021-2025 | 82 | US 18 | 93.27 |
| Neuroscience and Neuropharmacology Research | 2021-2025 | 609 | US 215 | 91.06 |
| Maternal Mental Health During Pregnancy and Postpartum | 2021-2025 | 530 | US 191 | 90.48 |
| Poisoning and overdose treatments | 2021-2025 | 91 | US 43 | 89.77 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 597 | US 153 | 85.40 |
| Sleep and Wakefulness Research | 2021-2025 | 794 | US 261 | 84.83 |
| Neuropeptides and Animal Physiology | 2021-2025 | 435 | US 150 | 80.50 |
| Hemispheric Asymmetry in Neuroscience | 2021-2025 | 64 | US 10 | 70.20 |
| Adenosine and Purinergic Signaling | 2021-2025 | 629 | US 102 | 69.27 |
| Alcoholism and Thiamine Deficiency | 2021-2025 | 190 | US 59 | 67.47 |
| Phosphodiesterase function and regulation | 2021-2025 | 702 | US 179 | 15.87 |
